Navigation Links
Accuray Announces Additions to Board of Directors
Date:9/15/2009

SUNNYVALE, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Accuray's Board of Directors has appointed Louis J. Lavigne, Jr. and Dennis L. Winger as members of the company's Board of Directors.

Lavigne is currently a management consultant specializing in the areas of corporate finance, accounting and strategy. Lavigne was Chief Financial Officer of Genentech, Inc., from 1988 and also served as the company's Executive Vice President from 1997 until his retirement in 2005. Lavigne sits on the Board of Trustees for Caltech (The California Institute of Technology) and also serves on the boards of directors of Allergan, Inc. and BMC Software, Inc., where he also chairs the Audit Committee.

Winger most recently served as Senior Vice President and Chief Financial Officer with Applied Biosystems, Inc. from 1997 to 2008. Prior to that, from 1989 to 1997, he was the Senior Vice President, Finance and Administration and Chief Financial Officer of Chiron Corporation. Winger also serves on the boards of directors of Cell Genesys, Inc., Cephalon, Inc. and Vertex Pharmaceuticals.

"We are pleased to have two of the industry's most skilled veterans join Accuray's Board of Directors, and we look forward to benefiting from their insight and experience," said Wayne Wu, Accuray Chairman.

It is expected that Lavigne will serve on the Audit Committee of the Board of Directors and Winger will serve on the Compensation Committee of the Board of the Directors.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 176 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to qualitative management experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: commercialization of products; market acceptance of products; competing products; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869


'/>"/>
SOURCE Accuray Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
2. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
3. Accuray to Webcast Senior Management Presentations at Analyst Day Event
4. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
5. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
6. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
7. Accuray Reports Record Revenue in First Quarter of Fiscal 2008
8. Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System
9. Accuray Incorporated to Report Second Quarter Fiscal Year 2008 Financial Results
10. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
11. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... during the Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 ... insurance coverage. Mainly, people are witnessing higher deductibles, rising premiums, and few choices ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... newest technology offering, Processing Assurance Control Equipment (PACE), at the International Production and ... , PeroxyChem’s booth will highlight the new technology that is used in poultry ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... product “Lacto-Freedom” was recently accepted as a Registered Trademark by the United States ... from using a similar name which could confuse consumers into thinking that other ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Learn to use ... athletics or even in relationships. Course offered by Dr. Carol Francis at PVNET ... to limited seating and the many hands-on experiences. , Dr. Carol Francis ...
(Date:1/24/2017)... ... January 24, 2017 , ... Seceon , the only ... real-time, today announced a strategic partnership with Paramount , the Middle East’s ... protect their critical information assets and infrastructure, in a comprehensive and cost effective ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , January 24, 2017 For today, ... GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... ), and Egalet Corp. (NASDAQ: EGLT ). These ... lower on Monday, January 23 rd , 2017, with the ... health care companies in the S&P 500 also were down ...
(Date:1/24/2017)... YORK , Jan. 23, 2017 Laboratory ... the global use of mass spectrometry in both clinical ... current ,MS analysis, global market size of $6.8 billion ... the next four years, profiles the use of mass ... encompassing 21 countries. This study investigated growth in the ...
(Date:1/24/2017)... , January 23, 2017 ArisGlobal, ... life sciences, announces agClinical 3.3, the latest version of ... enables life science organizations to confidently and efficiently meet ... better manage the electronic trial master file so that ... ...
Breaking Medicine Technology: